Regeneron Pharmaceuticals, Inc. | Large-cap | Healthcare
$522.27
2.02%
| Regeneron Stock Comparison:
Regeneron vs VertexRegeneron vs AlnylamRegeneron vs Royalty Pharma plcRegeneron vs InsmedRegeneron vs IncyteRegeneron vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 14.2B
Gross Profit 12.2B 86.13%
Operating Income 4.0B 28.10%
Net Income 4.4B 31.07%
EPS (Diluted) $38.34

Balance Sheet Metrics

Total Assets 37.8B
Total Liabilities 8.4B
Shareholders Equity 29.4B
Debt to Equity 0.29

Cash Flow Metrics

Operating Cash Flow 4.9B
Free Cash Flow 3.5B

Revenue & Profitability Trend

Regeneron Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue 14.2B 13.1B 12.2B 16.1B 8.5B
Cost of Goods Sold 2.0B 1.8B 1.6B 2.4B 1.1B
Gross Profit 12.2B 11.3B 10.6B 13.6B 7.4B
Operating Expenses 8.2B 7.1B 5.6B 4.6B 3.8B
Operating Income 4.0B 4.2B 5.0B 9.0B 3.6B
Pre-tax Income 4.8B 4.2B 4.9B 9.3B 3.8B
Income Tax 367.3M 245.7M 520.4M 1.3B 297.2M
Net Income 4.4B 4.0B 4.3B 8.1B 3.5B
EPS (Diluted) $38.34 $34.77 $38.22 $71.97 $30.52

Income Statement Trend

Regeneron Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets 18.7B 19.5B 15.9B 14.0B 9.8B
Non-Current Assets 19.1B 13.6B 13.3B 11.4B 7.4B
Total Assets 37.8B 33.1B 29.2B 25.4B 17.2B
Liabilities
Current Liabilities 3.9B 3.4B 3.1B 3.9B 2.7B
Non-Current Liabilities 4.5B 3.7B 3.4B 2.7B 3.4B
Total Liabilities 8.4B 7.1B 6.6B 6.7B 6.1B
Equity
Total Shareholders Equity 29.4B 26.0B 22.7B 18.8B 11.0B

Balance Sheet Composition

Regeneron Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income 4.4B 4.0B 4.3B 8.1B 3.5B
Operating Cash Flow 4.9B 4.4B 5.1B 7.7B 2.7B
Investing Activities
Capital Expenditures 20.1M - - - -
Investing Cash Flow -1.6B -2.3B -2.4B -4.8B 544.0M
Financing Activities
Dividends Paid - - - - -
Financing Cash Flow -2.2B -1.8B -1.0B -1.0B -2.0B
Free Cash Flow 3.5B 3.7B 3.4B 6.5B 2.0B

Cash Flow Trend

Regeneron Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 13.02
Forward P/E 11.30
Price to Book 1.84
Price to Sales 3.92
PEG Ratio 11.30

Profitability Ratios

Profit Margin 31.94%
Operating Margin 19.94%
Return on Equity 15.96%
Return on Assets 6.91%

Financial Health

Current Ratio 4.93
Debt to Equity 9.20
Beta 0.31

Per Share Data

EPS (TTM) $39.32
Book Value per Share $277.50
Revenue per Share $130.88

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
regn 55.3B 13.02 1.84 15.96% 31.94% 9.20
Vertex 117.0B 32.82 7.09 -5.64% -8.91% 10.00
Alnylam 40.8B - 353.42 -414.62% -11.49% 2,358.26
Royalty Pharma plc 20.3B 14.75 2.30 18.00% 48.26% 77.82
Insmed 20.0B - 193.43 -320.20% -265.93% 1,316.96
Incyte 13.0B 336.30 3.55 0.47% 0.48% 1.18

Financial data is updated regularly. All figures are in the company's reporting currency.